Onconova Therapeutics, Inc. (ONTX)

NASDAQ: ONTX · IEX Real-Time Price · USD
1.23
-0.03 (-2.38%)
At close: Aug 19, 2022 4:00 PM
1.27
+0.03 (2.85%)
After-hours: Aug 19, 2022 7:38 PM EDT
-2.38%
Market Cap 25.70M
Revenue (ttm) 226,000
Net Income (ttm) -15.36M
Shares Out 20.90M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 63,322
Open 1.23
Previous Close 1.26
Day's Range 1.23 - 1.26
52-Week Range 1.00 - 6.77
Beta 1.52
Analysts Buy
Price Target 10.20 (+729.3%)
Earnings Date Aug 11, 2022

About ONTX

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell... [Read more...]

Industry Pharmaceuticals
IPO Date Jul 25, 2013
CEO Steven Fruchtman
Employees 14
Stock Exchange NASDAQ
Ticker Symbol ONTX
Full Company Profile

Financial Performance

In 2021, ONTX's revenue was $226,000, a decrease of -2.16% compared to the previous year's $231,000. Losses were -$16.16 million, -35.75% less than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ONTX stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 729.27% from the latest price.

Price Target
$10.2
(729.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today

Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022

Onconova Therapeutics Announces Key Management Promotions

Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer

Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib's Differentiated Inhibi...

In vitro and cell-based assays suggest narazaciclib's inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6 inhibitors In vitro and cell-based assays suggest naraz...

Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today

Onconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual Meeting

NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients ...

Onconova Therapeutics to Present at the Next Generation Kinase Inhibitors Summit

NEWTOWN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients ...

Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2021 Financial Results on...

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022

Onconova Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

NEWTOWN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients w...

Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development

NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients w...

Recap: Onconova Therapeutics Q3 Earnings

Onconova Therapeutics (NASDAQ:ONTX) reported its Q3 earnings results on Thursday, November 11, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today

Earnings Outlook For Onconova Therapeutics

Onconova Therapeutics (NASDAQ:ONTX) is set to give its latest quarterly earnings report on Thursday, 2021-11-11. Here's what investors need to know before the announcement.

Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock

NEWTOWN, Pa., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products ...

Is the Options Market Predicting a Spike in Onconova (ONTX) Stock?

Investors need to pay close attention to Onconova (ONTX) stock based on the movements in the options market lately.

Onconova Therapeutics Raises $21M Via Equity At 17% Discount

Onconova Therapeutics Inc (NASDAQ: ONTX) has priced an underwritten public offering of 5 million shares at $4.20 for gross proceeds of $21 million. The offer price represents an almost 17% discount at t...

Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock

NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer...

Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

NEWTOWN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer...

Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer

Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control po...

Why Onconova Therapeutics Shares Are Surging Today

Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares are trading higher after the company reported preliminary data from a Phase 1/2 a trial of rigosertib plus immune checkpoint inhibitor nivolumab, which a...

ONTX Stock Is Soaring 25% on This Big Cancer Drug Update

Today, Oncova Therapeutics announced some positive preliminary trial results from one of its core cancer drugs, sending ONTX stock higher. The post ONTX Stock Is Soaring 25% on This Big Cancer Drug Upda...

Investors Cheer Onconova's Rigosertib Combo Data In Lung Cancer Setting

Onconova Therapeutics Inc (NASDAQ: ONTX) has announced preliminary data from Phase 1/2a trial of rigosertib plus Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in advanced KRAS mutated non-sma...